Page 15 - Poster Presentation News Today

National University of Science and Technology goes online for its first NUTechFest 2021 By: Times News Service Muscat: National University of Science and Technology in the Sultanate of Oman is a leading player in the higher education sector and is well known for its innovative initiatives and quest for social values. This year’s NUTech Fest adds one more feather to its cap by replacing the traditional face to face techfest event with a fully online one. To those who are not aware, the NUTech...

/PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic...

For a better future 27 Apr 2021 / 10:16 H. Gold Award winner Eng’s project involved the anti-diabetic properties of cinnamon-fortified cheese. (above) The project by Hew on a host-originated probiotic to improve growth efficacy of red tilapia fish also won a Gold Award. SCIENTIFIC research for industrial application is at the core of Tunku Abdul Rahman University College’s (TAR UC) applied science programmes. As such, applied science students are encouraged to conduct research projec...

Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimers Disease, Insomnia and Epilepsy Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimers disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome News provided by Share this article Share this article WOODCLIFF LAKE, N.J., April 16, 2021 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical...

STAFFORD, Texas--(BUSINESS WIRE)--Apr 10, 2021-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today presented a poster of the final 5 year GP2 Phase IIb clinical trial immune response data at the 2021 AACR Annual Meeting. Immune response is the primary mechanism of action for GP2 and is cr...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association ... Merus N.V.March 10, 2021 GMT UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® an...

(2) UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021(Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Merus will present preclinical data from our zenocutuzumab and MCLA-129 programs in three poster presentations at the American Association for Cancer Research 2021 Annual Meeting being held virtually for two weeks, April 10-15, 2021 ...

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing new treatment options for cancer patients in...

Merus N.V. Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a c...

Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium Oral presentation showcases the largest early-stage CRC cohort to date, further validating the serial use of Signatera™ for early recurrence detection and MRD assessment News provided by Share this article SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed mo...